Profile
Gudrun Bachmann currently works at Oculis Holding AG, as Chief Technology Officer from 2024.
Dr. Bachmann also formerly worked at Sandoz AG, as Head-Biopharmaceutical Development from 2012 to 2014, Fresenius Kabi Schweiz AG, as Global Head-CMC leads from 2020 to 2022, and Alvotech hf, as Head-Drug Product Biopharmaceutical Development from 2015 to 2018.
Dr. Bachmann received her graduate degree from the University of Aalborg and doctorate degree from Institute of Cancer Research Royal Marsden Hospital.
Gudrun Bachmann active positions
| Companies | Position | Start |
|---|---|---|
| OCULIS HOLDING AG | Chief Tech/Sci/R&D Officer | 2024-08-31 |
Former positions of Gudrun Bachmann
| Companies | Position | End |
|---|---|---|
Fresenius Kabi Schweiz AG | Corporate Officer/Principal | 2021-12-31 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Corporate Officer/Principal | 2017-12-31 |
Sandoz AG
Sandoz AG Pharmaceuticals: GenericHealth Technology Develops generic medicines and biosimilars | Corporate Officer/Principal | 2013-12-31 |
Training of Gudrun Bachmann
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Sandoz AG
Sandoz AG Pharmaceuticals: GenericHealth Technology Develops generic medicines and biosimilars | Health Technology |
University of Aalborg
University of Aalborg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fresenius Kabi Schweiz AG | |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Institute of Cancer Research Royal Marsden Hospital
Institute of Cancer Research Royal Marsden Hospital Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oculis Holding AG
Oculis Holding AG Miscellaneous Commercial ServicesCommercial Services Operates as a global biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases | Commercial Services |
- Stock Market
- Insiders
- Gudrun Bachmann
















